The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Radoja, S.
Right arrow Articles by Frey, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radoja, S.
Right arrow Articles by Frey, A. B.
The Journal of Immunology, 2000, 164: 2619-2628.
Copyright © 2000 by The American Association of Immunologists

Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo1

Sasa Radoja*,{dagger}, T. Dharma Rao*, Deborah Hillman* and Alan B. Frey2,*

* Department of Cell Biology and Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016; and {dagger} The Institute of Molecular Genetics and Genetic Engineering, Belgrade, Yugoslavia

Immune suppression in tumor-bearing hosts is considered to be one factor causally associated with the growth of antigenic tumors. Support for this hypothesis has come from reports that spleen T cells in tumor-bearing mice are deficient in either priming or effector phase functions. We have reexamined this hypothesis in detail using multiple murine tumor models, including transplantable adenocarcinoma, melanoma, sarcoma, and thymoma, and also a transgenic model of spontaneous breast carcinoma. In both in vitro and in vivo assays of T cell function (proliferation, cytokine production, induction of CD8+ alloreactive CTL, and development of anti-keyhole limpet hemocyanin CD4+ T cells, rejection of allogeneic or syngeneic regressor tumors, respectively) we show that mice bearing sizable tumor burdens are not systemically suppressed and do not have diminished T cell functions. Therefore, if immune suppression is a causal function in the growth of antigenic tumor, the basis for escape from immune destruction is likely to be dependent upon tumor-induced T cell dysfunction at the site of tumor growth.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
N. Monu and A. B. Frey
Suppression of Proximal T Cell Receptor Signaling and Lytic Function in CD8+ Tumor-Infiltrating T Cells
Cancer Res., December 1, 2007; 67(23): 11447 - 11454.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. J. Stewart and S. I. Abrams
Altered Immune Function during Long-Term Host-Tumor Interactions Can Be Modulated to Retard Autochthonous Neoplastic Growth
J. Immunol., September 1, 2007; 179(5): 2851 - 2859.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Koneru, N. Monu, D. Schaer, J. Barletta, and A. B. Frey
Defective Adhesion in Tumor Infiltrating CD8+ T Cells
J. Immunol., May 15, 2006; 176(10): 6103 - 6111.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. B. Frey and N. Monu
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response
J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Kusmartsev and D. I. Gabrilovich
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
J. Immunol., April 15, 2005; 174(8): 4880 - 4891.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Koneru, D. Schaer, N. Monu, A. Ayala, and A. B. Frey
Defective Proximal TCR Signaling Inhibits CD8+ Tumor-Infiltrating Lymphocyte Lytic Function
J. Immunol., February 15, 2005; 174(4): 1830 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. A. Danna, P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg
Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease
Cancer Res., March 15, 2004; 64(6): 2205 - 2211.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. M. Prins, F. Incardona, R. Lau, P. Lee, S. Claus, W. Zhang, K. L. Black, and C. J. Wheeler
Characterization of Defective CD4-CD8- T Cells in Murine Tumors Generated Independent of Antigen Specificity
J. Immunol., February 1, 2004; 172(3): 1602 - 1611.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Yang, C. E. Monken, and E. C. Lattime
Intratumoral Vaccination with Vaccinia-Expressed Tumor Antigen and Granulocyte Macrophage Colony-Stimulating Factor Overcomes Immunological Ignorance to Tumor Antigen
Cancer Res., October 15, 2003; 63(20): 6956 - 6961.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Saio, S. Radoja, M. Marino, and A. B. Frey
Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide
J. Immunol., November 15, 2001; 167(10): 5583 - 5593.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Radoja, M. Saio, and A. B. Frey
CD8+ Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ
J. Immunol., May 15, 2001; 166(10): 6074 - 6083.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page

Vet. Pathol., September 1, 2000; 37(5): 517 - 518.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.